Excelsior Biopharma Inc. (TPEX:6496)
Taiwan · Delayed Price · Currency is TWD 22.85
-0.25 (-1.08%)
May 29, 2026, 1:30 PM CST
Excelsior Biopharma Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 130.61 | 185.34 | 240.08 | 589.92 | 895.28 | 1,103 |
Short-Term Investments | - | - | 11.45 | - | 211.19 | - |
Cash & Short-Term Investments | 130.61 | 185.34 | 251.53 | 589.92 | 1,106 | 1,103 |
Cash Growth | -23.69% | -26.31% | -57.36% | -46.68% | 0.34% | -4.25% |
Accounts Receivable | 205.38 | 235.01 | 187.49 | 160.53 | 135.03 | 213.06 |
Other Receivables | 1.4 | 0.7 | 1.21 | 2.19 | 2.95 | 1.46 |
Receivables | 206.78 | 235.71 | 188.71 | 162.73 | 137.98 | 214.51 |
Inventory | 331.92 | 285.18 | 302.93 | 217.28 | 188.58 | 204.6 |
Other Current Assets | 22.62 | 20.01 | 30.54 | 14.17 | 10.09 | 10.81 |
Total Current Assets | 691.92 | 726.24 | 773.7 | 984.09 | 1,443 | 1,533 |
Property, Plant & Equipment | 376.85 | 392.51 | 431.86 | 445.91 | 164.61 | 188.08 |
Long-Term Investments | 87.97 | 91.39 | 96.4 | 68.18 | 69.44 | 74.14 |
Other Intangible Assets | 0.01 | 0.01 | 0.03 | 0.04 | 0.06 | 0.07 |
Long-Term Deferred Tax Assets | 18.28 | 18.28 | 19.94 | 20.05 | 20.16 | 21.23 |
Other Long-Term Assets | 255.21 | 255.58 | 256.42 | 59.04 | 17.59 | 22.84 |
Total Assets | 1,430 | 1,484 | 1,578 | 1,577 | 1,715 | 1,839 |
Accounts Payable | 90.29 | 48.03 | 92.56 | 45.42 | 63.75 | 121.51 |
Accrued Expenses | - | 5.24 | 4.91 | 4.4 | 3.99 | 2.34 |
Short-Term Debt | 159.83 | 159.61 | - | - | - | - |
Current Portion of Long-Term Debt | - | - | - | - | 297.45 | - |
Current Portion of Leases | 49.23 | 49.76 | 55.02 | 53.97 | 10.75 | 13.7 |
Current Income Taxes Payable | 3.52 | 3.52 | 6.93 | 4.9 | 3.92 | 4.1 |
Other Current Liabilities | 85.63 | 105.44 | 66.35 | 57.59 | 78.77 | 108.62 |
Total Current Liabilities | 388.5 | 371.6 | 225.77 | 166.28 | 458.64 | 250.27 |
Long-Term Debt | 110 | 110 | 110 | - | - | 293.99 |
Long-Term Leases | 179.66 | 191.94 | 245.58 | 300.25 | 43.04 | 56.94 |
Pension & Post-Retirement Benefits | - | 4.53 | 4.57 | 6.34 | 5.85 | 7.7 |
Other Long-Term Liabilities | 6.24 | 1.71 | 0.98 | - | - | - |
Total Liabilities | 684.39 | 679.78 | 586.89 | 472.87 | 507.53 | 608.9 |
Common Stock | 473.96 | 473.96 | 475.64 | 477.92 | 475.07 | 466.67 |
Additional Paid-In Capital | 259.16 | 259.16 | 256.07 | 253.78 | 255.2 | 263.24 |
Retained Earnings | 27.03 | 81.78 | 264.88 | 362.13 | 453.37 | 482.6 |
Treasury Stock | -23.74 | -23.74 | -23.74 | -23.74 | -23.74 | -23.74 |
Comprehensive Income & Other | 9.42 | 13.07 | 18.6 | 34.36 | 47.53 | 41.36 |
Shareholders' Equity | 745.84 | 804.23 | 991.45 | 1,104 | 1,207 | 1,230 |
Total Liabilities & Equity | 1,430 | 1,484 | 1,578 | 1,577 | 1,715 | 1,839 |
Total Debt | 498.72 | 511.31 | 410.59 | 354.22 | 351.24 | 364.63 |
Net Cash (Debt) | -368.11 | -325.98 | -159.07 | 235.7 | 755.23 | 738.13 |
Net Cash Growth | - | - | - | -68.79% | 2.32% | -5.08% |
Net Cash Per Share | -7.62 | -7.06 | -3.45 | 5.13 | 16.47 | 15.87 |
Filing Date Shares Outstanding | 54.74 | 46.58 | 46.75 | 46.97 | 46.69 | 45.85 |
Total Common Shares Outstanding | 54.74 | 46.58 | 46.75 | 46.97 | 46.69 | 45.85 |
Working Capital | 303.43 | 354.64 | 547.93 | 817.81 | 984.48 | 1,282 |
Book Value Per Share | 13.62 | 17.27 | 21.21 | 23.51 | 25.86 | 26.83 |
Tangible Book Value | 745.83 | 804.22 | 991.42 | 1,104 | 1,207 | 1,230 |
Tangible Book Value Per Share | 13.62 | 17.27 | 21.21 | 23.51 | 25.86 | 26.83 |
Land | - | - | - | 37.26 | 37.26 | 37.26 |
Buildings | - | - | - | 72.75 | 72.75 | 72.75 |
Machinery | - | 389.96 | 355.23 | 221.15 | 213.92 | 209.29 |